Clinical Trial Update: RGX-111 Gene Therapy in Patients With MPS I [Phase 1, Phase 2]

View source ↗

Summary

The RGX-111 gene therapy trial for Mucopolysaccharidosis Type I is currently suspended in Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hurler Syndrome
• Hurler-scheie Syndrome
• Mucopolysaccharidosis Type

Drugs mentioned

• RGX-111

Snippet

Sponsor: REGENXBIO Inc. | Conditions: Mucopolysaccharidosis Type I (MPS I), Hurler Syndrome | Phase 1, Phase 2 | Status: SUSPENDED